British Journal of Clinical Pharmacology

Article	Citations
Recent developments of HDAC inhibitors: Emerging indications and novel molecules	215
Potentially inappropriate prescribing and its associations with health‐related and system‐related outcomes in hospitalised older adults: A systematic review and meta‐analysis	75
Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside—a systematic review and meta‐analysis	63
Machine learning in pharmacometrics: Opportunities and challenges	59
Pharmacovigilance‐based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections	56
Safety and efficacy of fluvoxamine in COVID‐19 ICU patients: An open label, prospective cohort trial with matched controls	51
Fatal adverse drug reactions: A worldwide perspective in the World Health Organization pharmacovigilance database	46
Drug–drug interactions with warfarin: A systematic review and meta‐analysis	46
Warfarin dosing algorithms: A systematic review	45
Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO	45
Night‐time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole	45
Identification of different side effects between PARP inhibitors and their polypharmacological multi‐target rationale	45
Trends in polypharmacy and potentially inappropriate medication (PIM) in older and middle‐aged people treated for diabetes	41
Effect of lipophilicity on drug distribution and elimination: Influence of obesity	39
Learning from remote decentralised clinical trial experiences: A qualitative analysis of interviews with trial personnel, patient representatives and other stakeholders	39
Pharmacokinetics, pharmacodynamics and safety of BAY 2433334, a novel activated factor XI inhibitor, in healthy volunteers: A randomized phase 1 multiple‐dose study	38
Dissecting the IL‐6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R	38
Changes in antibiotic prescribing following COVID‐19 restrictions: Lessons for post‐pandemic antibiotic stewardship	38
The environmental impact of inhalers for asthma: A green challenge and a golden opportunity	37
Zinc supplementation as an adjunct therapy for COVID‐19: Challenges and opportunities	37
Pharmacovigilance in low‐ and middle‐income countries: A review with particular focus on Africa	37
Dose prediction for repurposing nitazoxanide in SARS‐CoV‐2 treatment or chemoprophylaxis	37
Review of pharmacological options for the treatment of Chagas disease	36
A systematic review of methods used to conduct decentralised clinical trials	36
The median effective concentration of propofol with different doses of esketamine during gastrointestinal endoscopy in elderly patients: A randomized controlled trial	36

A placebo‐controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans	35
Pharmacological profile and effects of mitotane in adrenocortical carcinoma	34
Antiplatelet therapy in cardiovascular disease: Current status and future directions	34
Statin liver safety in non‐alcoholic fatty liver disease: A systematic review and metanalysis	33
A randomized single and multiple ascending dose study in healthy volunteers of LTI‐291, a centrally penetrant glucocerebrosidase activator	32
Ethical issues in therapeutic use and research in pregnant and breastfeeding women	31
Community‐based pharmacists' role in deprescribing: A systematic review	30
Health equality, race and pharmacogenomics	29
Liver and kidney function in patients with Covid‐19 treated with remdesivir	29
Drug‐induced peripheral oedema: An aetiology‐based review	29
Oral drug dosing following bariatric surgery: General concepts and specific dosing advice	28
Impact of the Goal‐directed Medication Review Electronic Decision Support System on Drug Burden Index: A cluster‐randomised clinical trial in primary care	27
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology	27
Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White	27
Does metformin affect outcomes in COVID‐19 patients with new or pre‐existing diabetes mellitus? A systematic review and meta‐analysis	26
Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: A prospective observational study	26
Performance of creatinine‐based equations to estimate glomerular filtration rate with a methodology adapted to the context of drug dosage adjustment	26
TEOS: A framework for constructing operational definitions of medication adherence based on Timelines–Events–Objectives–Sources	26
Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects	26
Comparison of infection risks and clinical outcomes in patients with and without SARS‐CoV‐2 lung infection under renin–angiotensin–aldosterone system blockade: Systematic review and meta‐analysis	25
Ketamine treatment for refractory anxiety: A systematic review	25
Volumetric microsampling for simultaneous remote immunosuppressant and kidney function monitoring in outpatient kidney transplant recipients	25
Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement	25
Hypertension: Current trends and future perspectives	25
Evaluation of safety and pharmacokinetics of bismuth‐containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication	25
Emerging therapeutic drug monitoring of anti‐infective agents in Australian hospitals: Availability, performance and barriers to implementation	24
A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as single‐dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers	24
Association of proton‐pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta‐analyses of cohort studies and randomised controlled trials	24
Is there scope for better individualisation of anthracycline cancer chemotherapy?	24
Dexamethasone use and mortality in hospitalized patients with coronavirus disease 2019: A multicentre retrospective observational study	24
Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5‐fluorouracil to	24
Efficacy and safety of roxadustat for anaemia in dialysis‐dependent and non‐dialysis‐dependent chronic kidney disease patients: A systematic review and meta‐analysis	23
Clinical trial diversity: An opportunity for improved insight into the determinants of variability in drug response	23
Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients	22
Switching between reference adalimumab and biosimilars in chronic immune‐mediated inflammatory diseases: A systematic literature review	22
Domperidone and the risks of sudden cardiac death and ventricular arrhythmia: A systematic review and meta‐analysis of observational studies	22
The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation	22
ONO‐7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first‐in‐human study	22
Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria	21
Bisphosphonate nephropathy: A case series and review of the literature	21
Evaluating the performance of ChatGPT in clinical pharmacy: A comparative study of ChatGPT and clinical pharmacists	21
Adverse outcomes of proton pump inhibitors in patients with chronic kidney disease: The CKD‐REIN cohort study	21
Comparison of 95% effective dose of remimazolam besylate and propofol for gastroscopy sedation on older patients: A single‐centre randomized controlled trial	20
Prior use of therapeutic anticoagulation does not protect against COVID‐19 related clinical outcomes in hospitalized patients: A propensity score‐matched cohort study	20
Development of a physiologically based pharmacokinetic (PBPK) population model for Chinese elderly subjects	20
A Phase 1 study of the long‐acting anti‐IL‐5 monoclonal antibody GSK3511294 in patients with asthma	20
Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS)	20
Pharmacist‐led interventions to reduce adverse drug events in older people living in residential aged care facilities: A systematic review	20
Riociguat: Clinical research and evolving role in therapy	20
Association study between herpes zoster reporting and mRNA COVID‐19 vaccines (BNT162b2 and mRNA‐1273)	20

A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics	20
Sulfate conjugation may be the key to hepatotoxicity in paracetamol overdose	20
Combination therapies for COVID‐19: An overview of the clinical trials landscape	19
Proton pump inhibitors and risk of all‐cause and cause‐specific mortality: A cohort study	19
Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID‐19: A multicentre case series of 98 patients	18
Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: Results of a phase 1a/b randomised double‐bl	18
Risk factors for vancomycin‐associated acute kidney injury: A systematic review and meta‐analysis	18
Disease‐modifying agents for multiple sclerosis and the risk for reporting cancer: A disproportionality analysis using the US Food and Drug Administration Adverse Event Reporting System database	18
Prenatal exposure to antipsychotic agents and the risk of congenital malformations in children: A systematic review and meta‐analysis	18
Are vancomycin dosing guidelines followed? A mixed methods study of vancomycin prescribing practices	18
Hospitalization for COVID‐19 in patients treated with selected immunosuppressant and immunomodulating agents, compared to the general population: A Danish cohort study	18
Short‐ and long‐term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity	18
Effect of renal function on the risk of thrombocytopaenia in patients receiving linezolid therapy: A systematic review and meta‐analysis	18
Haemophilia, state of the art and new therapeutic opportunities, a regulatory perspective	18
Identifying and addressing pill aversion in adults without physiological‐related dysphagia: A narrative review	18
Measuring prescription opioid misuse and its consequences	18
Estimating the potential impact of implementing pre‐emptive pharmacogenetic testing in primary care across the UK	18
Thromboembolic events in Janus kinase inhibitors: A pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration's Adverse Event Reporting System	17
Pharmacist‐led intervention on chronic pain management: A systematic review and meta‐analysis	17
Rethinking the role of Research Ethics Committees in the light of Regulation (EU) No 536/2014 on clinical trials and the COVID‐19 pandemic	17
Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID‐19; a systematic review and meta‐analysis of randomized clinical trials	17
Achievements and challenges of the Sakigake designation system in Japan	17
Constructing a representative in‐silico population for paediatric simulations: Application to HIV‐positive African children	17
Proton pump inhibitors are associated with incident type 2 diabetes mellitus in a prospective population‐based cohort study	17
Optimization of voriconazole therapy for treatment of invasive aspergillosis: Pharmacogenomics and inflammatory status need to be evaluated	17
Novel long‐acting ropeginterferon alfa‐2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial	17
The association between proton pump inhibitor use and systemic anti‐tumour therapy on survival outcomes in patients with advanced non‐small cell lung cancer: A systematic review and meta‐analysis	17
Population pharmacokinetics of mycophenolic acid in paediatric patients	17
Precision therapy with quinidine of KCNT1‐related epileptic disorders: A systematic review	17
Pharmacovigilance in China: Evolution and future challenges	17
Antihistamine‐related deaths in England: Are the high safety profiles of antihistamines leading to their unsafe use?	17
Impact of pharmacist‐led medication therapy management in ambulatory elderly patients with chronic diseases	17
Efficacy and safety of colchicine in patients with coronary artery disease: A systematic review and meta‐analysis of randomized controlled trials	17
INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID‐19 (INHALE‐HEP): Protocol and statistical analysis plan for an investigator‐initiated international metat	17
A case of acute necrotising pancreatitis following the second dose of Pfizer‐BioNTech COVID‐19 mRNA vaccine	17
The Dutch chain approach on pharmaceuticals in water: Stakeholders acting together to reduce the environmental impact of pharmaceuticals	17
Immunomodulatory effects of pharmaceutical opioids and antipyretic analgesics: Mechanisms and relevance to infection	16
First‐in‐human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics	16
Fatalities associated with gabapentinoids in England (2004–2020)	16
The effects of saffron (Crocus sativus L.) in conjunction with concurrent training on body composition, glycaemic status, and inflammatory markers in obese men with type 2 diabetes m	16
Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: A pharmacometric model‐based approach	16
Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long‐acting C‐type natriuretic peptide prodrug, TransCon CNP	16
Incidence and preventability of hospital admissions for adverse drug reactions in France: A prospective observational study (IATROSTAT)	16
Towards better reporting of the proportion of days covered method in cardiovascular medication adherence: A scoping review and new tool TEN‐SPIDERS	16
Medication‐related osteonecrosis of the jaw: Analysing the range of implicated drugs from the Australian database of adverse event notifications	16
Population pharmacokinetics and pharmacodynamics of Tranexamic acid in women undergoing caesarean delivery	16
Who prescribes drugs to patients: A Danish register‐based study	16
Antithyroid drug use during pregnancy and the risk of birth defects in offspring: systematic review and meta‐analysis of observational studies with methodological considerations	16
Cognitive decline associated with anticholinergics, benzodiazepines and Z‐drugs: Findings from The Irish Longitudinal Study on Ageing (TILDA)	16
Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target	16
Developing a physiologically based pharmacokinetic model of apixaban to predict scenarios of drug–drug interactions, renal impairment and paediatric populations	15
Trough polymyxin B plasma concentration is an independent risk factor for its nephrotoxicity	15
Efficacy of targeted therapy in patients with HER2‐positive non‐small cell lung cancer: A systematic review and meta‐analysis	15
Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients	15
Exosomes and extracellular vesicles as liquid biopsy biomarkers in diffuse large B‐cell lymphoma: Current state of the art and unmet clinical needs	15
Impact of glucagon‐like peptide‐1 receptor agonists on adiponectin concentrations: A meta‐analysis of randomized controlled trials	15
Pharmacokinetic characterization of favipiravir in patients with COVID‐19	15
Racing to immunity: Journey to a COVID‐19 vaccine and lessons for the future	15
Development and validation of the Adverse Inpatient Medication Event model (AIME)	15
Challenges of drug development during the COVID‐19 pandemic: Key considerations for clinical trial designs	15
Dose‐dependent glucosuria of DWP16001, a novel selective sodium–glucose cotransporter‐2 inhibitor, in healthy subjects	15
Population pharmacokinetics and exposure‐response analysis of tigecycline in patients with hospital‐acquired pneumonia	15
Impact of P‐glycoprotein and/or CYP3A4‐interacting drugs on effectiveness and safety of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A meta‐analysis	15
Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects	15
Rapid review and meta‐analysis of adverse events associated with molnupiravir in patients with COVID‐19	15
Effectiveness of a targeted and tailored pharmacist‐led intervention to improve adherence to antihypertensive drugs among patients with type 2 diabetes in Indonesia: A cluster randomised controlled tr	15
Disproportionality analysis in VigiBase as a drug repositioning method for the discovery of potentially useful drugs in Alzheimer's disease	15
Physiologically‐based pharmacokinetic model predictions of inter‐ethnic differences in imatinib pharmacokinetics and dosing regimens	14
Effects of inflammation on voriconazole levels: A systematic review	14
Antihypertensive medications and COVID‐19 diagnosis and mortality: Population‐based case‐control analysis in the United Kingdom	14
Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant, a dual orexin receptor antagonist	14
Pharmacokinetics of amoxicillin in obese and nonobese subjects	14
Comprehensive evaluation of microneedle‐based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trial	14
Alpelisib to treat CLOVES syndrome, a member of the PIK3CA‐related overgrowth syndrome spectrum	14
Recent advances in the ontogeny of drug disposition	14
Bivalirudin vs. heparin in paediatric and adult patients on extracorporeal membrane oxygenation: A meta‐analysis	14
Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system	14
Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P‐gp and BCRP	14
Conceiving, conducting, reporting, interpreting, and publishing disproportionality analyses: A call to action	14
MicroRNA‐122 and cytokeratin‐18 have potential as a biomarkers of drug‐induced liver injury in European and African patients on treatment for mycobacterial infection	14

COVID‐19: Clinical status of vaccine development to date	14
Active‐comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors	14
Proteomics of colorectal cancer liver metastasis: A quantitative focus on drug elimination and pharmacodynamics effects	14
Multiparametric magnetic resonance imaging to characterize cabotegravir long‐acting formulation depot kinetics in healthy adult volunteers	14
Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis	14
Health literacy for children and families	14
The effect of glucagon‐like peptide‐1 receptor agonists on serum uric acid concentration: A systematic review and meta‐analysis	14
Traditional medicines for COVID‐19: Perspectives from clinical pharmacologists	14
External evaluation of population pharmacokinetic models of imatinib in adults diagnosed with chronic myeloid leukaemia	13
Nitrous oxide‐induced neurotoxicity: A case report and literature review	13
Identifying adverse drug reactions from free‐text electronic hospital health record notes	13
Modelling item scores of Unified Parkinson's Disease Rating Scale Part III for greater trial efficiency	13
Accuracy of documented administration times for intravenous antimicrobial drugs and impact on dosing decisions	13
Pharmacogenomic testing in paediatrics: Clinical implementation strategies	13
Interferon‐α‐2b aerosol inhalation is associated with improved clinical outcomes in patients with coronavirus disease‐2019	13
Impact of spironolactone exposure on prostate cancer incidence amongst men with heart failure: A Pharmacoepidemiological study	13
A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status	13
Drugs and the skin: A concise review of cutaneous adverse drug reactions	13
Impact of CYP2D6 on serum concentrations of flupentixol, haloperidol, perphenazine and zuclopenthixol	13
The role of behavioural science in changing deprescribing practice	13
Systematic review of machine learning models for personalised dosing of heparin	13
Population pharmacokinetics of vancomycin in patients with external ventricular drain‐associated ventriculitis	13
Effective low–dose sirolimus regimen for kaposiform haemangioendothelioma with Kasabach–Merritt phenomenon in young infants	13
Hospitalization for adverse events under abiraterone or enzalutamide exposure in real‐world setting: A French population‐based study on prostate cancer patients	13
A systematic literature review and meta‐analysis of community pharmacist‐led interventions to optimise the use of antibiotics	13
Appropriate and inappropriate polypharmacy—Choosing the right strategy	13
Cardiovascular drugs and COVID‐19 clinical outcomes: A living systematic review and meta‐analysis	13
Parametric population pharmacokinetics of linezolid: A systematic review	13
Adverse events of recreational cannabis use reported to the French addictovigilance network (2012–2017)	13
Change in the regulatory framework for zolpidem: What is the impact on the landscape of the prescription of sedative medications? The French national ZORRO study	13
A meta‐analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis	13
Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies	13
Population pharmacokinetic‐pharmacodynamic model‐based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease	13
Economic evaluation of remdesivir for the treatment of severe COVID‐19 patients in China under different scenarios	12
Needs‐driven talent and competency development for the next generation of regulatory scientists in Africa	12
Multicompartmental pharmacokinetic evaluation of long‐acting cabotegravir in healthy adults for HIV preexposure prophylaxis	12
Considerations on the use of different comparators in pharmacovigilance: A methodological review	12
Methodological considerations on estimating medication adherence from self‐report, electronic monitoring and electronic healthcare databases using the TEOS framework	12
Concomitant use of statins and sodium‐glucose co‐transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis	12
Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: A multi‐database cohort study with meta‐analysis	12
Remote clinical trials: A timely opportunity for a virtual reality approach and its potential application in neurology	12
Dealing with doping. A plea for better science, governance and education	12
Do proton pump inhibitors increase the risk of dementia? A systematic review, meta‐analysis and bias analysis	12
Artificial intelligence and machine learning for clinical pharmacology	12
Quantitative impact of pre‐analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency	12
Intestinal SGLT1 as a therapeutic target in COVID‐19‐related diabetes: A “two‐edged sword” hypothesis	12
Safety, tolerability and pharmacokinetics of emodepside, a potential novel treatment for onchocerciasis (river blindness), in healthy male subjects	12
Concentration–response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy	12
Overcoming barriers to implementing precision dosing with 5‐fluorouracil and capecitabine	12
Pharmacokinetics under the COVID‐19 storm	12
Population pharmacokinetics of tenofovir, emtricitabine and intracellular metabolites in transgender women	12
Path towards efficient paediatric formulation development based on partnering with clinical pharmacologists and clinicians, a conect4children expert group white paper	12
Is polypharmacy associated with mortality in the very old: Findings from the Newcastle 85+ Study	12
Prediction of maternal and fetal pharmacokinetics of indomethacin in pregnancy	12
Mycophenolic acid and cancer risk in solid organ transplant recipients: Systematic review and meta‐analysis	12
L‐lysine: Its antagonism with L‐arginine in controlling viral infection. Narrative literature review	12
Dose–response association of acute‐phase quetiapine treatment with risk of new‐onset hypothyroidism in schizophrenia patients	12
How do they add up? The interaction between the placebo and treatment effect: A systematic review	12
Increase of high‐risk tramadol use and harmful consequences in France from 2013 to 2018: Evidence from the triangulation of addictovigilance data	12
Clinical studies assessing the efficacy, effectiveness and safety of remdesivir in management of COVID‐19: A scoping review	12
Risk–efficacy balance of ulipristal acetate compared to surgical alternatives	12
Paediatric oral formulations: Why don't our kids have the medicines they need?	12
Incidence, characteristics and risk factors for drug‐induced liver injury in hospitalized patients: A matched case‐control study	12
Population pharmacokinetics and target attainment analysis of linezolid in multidrug‐resistant tuberculosis patients	11
Phase I evaluation of pharmacokinetics and tolerability of the HIV‐1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults	11
Role of TDM‐based dose adjustments for taxane anticancer drugs	11
Genetic variants associated with severe cutaneous adverse drug reactions induced by carbamazepine	11
Meropenem pharmacokinetics in critically ill patients with or without burn treated with or without continuous veno‐venous haemofiltration	11
Determinants for under‐ and overdosing of direct oral anticoagulants and physicians' implementation of clinical pharmacists' recommendations	11
Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers	11
Association between opioid‐related deaths and persistent opioid prescribing in primary care in England: A nested case‐control study	11
DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine‐based protocols	11
Dual bronchodilation for the treatment of COPD: From bench to bedside	11
Evaluation of the pharmacokinetics of pemigatinib in patients with impaired hepatic or renal function	11
From paediatric formulations development to access: Advances made and remaining challenges	11
Lung and liver sarcoidosis‐like reaction induced by tocilizumab	11
Medicine misuse: A systematic review and proposed hierarchical terminology	11
N‐of‐1 trials to facilitate evidence‐based deprescribing: Rationale and case study	11
Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis	11
Antihypertensive drug use and psoriasis: A systematic review, meta‐ and network meta‐analysis	11
Model‐informed drug repurposing: A pharmacometric approach to novel pathogen preparedness, response and retrospection	11
Prevalence of NSAID use among people with COVID‐19 and the association with COVID‐19‐related outcomes: Systematic review and meta‐analysis	11
Drug interaction of ningetinib and gefitinib involving CYP1A1 and efflux transporters in non‐small cell lung cancer patients	11
Medication therapy of high‐dose methotrexate: An evidence‐based practice guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society	11
Investigating the interaction between nifedipine‐ and ritonavir‐containing antiviral regimens: A physiologically based pharmacokinetic/pharmacodynamic analysis	11
Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System	10
Safety, pharmacokinetics and pharmacodynamics of TAK‐418, a novel inhibitor of the epigenetic modulator lysine‐specific demethylase 1A	10
Angiotensin II receptor blockers (ARBs) and manufacturing contamination: A retrospective National Register Study into suspected associated adverse drug reactions	10
Cardiovascular complications of modern multiple myeloma therapy: A pharmacovigilance study	10
Comparison between physiologically based pharmacokinetic and population pharmacokinetic modelling to select paediatric doses of gepotidacin in plague	10
Numbers of spontaneous reports: How to use and interpret?	10
Population pharmacokinetic/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis	10
c4c: Paediatric pharmacovigilance: Methodological considerations in research and development of medicines for children – A c4c expert group white paper	10
Anticoagulation in sub‐Saharan Africa: Are direct oral anticoagulants the answer? A review of lessons learnt from warfarin	10
Can nebulised HepArin Reduce morTality and time to Extubation in patients with COVID‐19 Requiring invasive ventilation Meta‐Trial (CHARTER‐MT): Protocol and statistical analysis plan for an investigat	10